<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756895</url>
  </required_header>
  <id_info>
    <org_study_id>2021-600</org_study_id>
    <nct_id>NCT04756895</nct_id>
  </id_info>
  <brief_title>Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population</brief_title>
  <acronym>VancoDATABayes</acronym>
  <official_title>Vancomycin Dose Adjustments Comparing Trough Levels to The AUC0-24h/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CR-CSSS Champlain-Charles-Le Moyne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CR-CSSS Champlain-Charles-Le Moyne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is a prospective, randomized, controlled, open-label trial to assess the&#xD;
      feasibility of a randomized controlled trial of sufficient quality that would assess the&#xD;
      efficacy and safety of vancomycin adjustments according to Area under the curve/Minimal&#xD;
      inhibitory concentration (AUC0-24h/MIC) calculated by the Bayesian approach rather than by a&#xD;
      trough dosage. Randomization will be stratified according to infection severity.&#xD;
      Approximately 60 subjects meeting all inclusion and no exclusion criteria will be randomized&#xD;
      to have pharmacists perform vancomycin dose adjustments with AUC0-24h / MIC calculated by the&#xD;
      Bayesian approach versus the trough dosage approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">August 6, 2021</completion_date>
  <primary_completion_date type="Actual">August 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of The Research Protocol</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Evaluation of adhesion rate to the sampling protocol of 80% or more and adhesion rate to software recommendations of 90% or more</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Recruitment</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluation of consent rate of 30% or more and the number of patients recruited per month of 10 or more</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who reach a therapeutic level in the first 48 hours</measure>
    <time_frame>At 48 hours after the first dose of vancomycin</time_frame>
    <description>Percentage of patients who reach a therapeutic level in the first 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the vancomycin target</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>Number of hours necessary to reach the vancomycin target. Number of hours will be classified in the following categories: 24-48 hours, 49-96 hours, 97 hours and above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of adjustments required to reach the vancomycin target</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>Number of dose adjustments required to reach the vancomycin target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of vancomycin dosage level monitoring to reach the vancomycin target</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>The number of vancomycin dosage level monitoring to reach the vancomycin target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of vancomycin dosage level monitoring in the vancomycin target</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>Percentage of vancomycin dosage level monitoring in the vancomycin target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between the AUC calculated by the Bayesian method and the trapezoid method</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>Difference in percentage of the vancomycin AUC calculated by the Bayesian method and the trapezoid method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between the initial prescribed dose and the dose suggested by the Bayesian software.</measure>
    <time_frame>Baseline</time_frame>
    <description>Difference in percentage of the initial prescribed dose and the dose suggested by the Bayesian software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of acute kidney injury</measure>
    <time_frame>During the vancomycin treatment</time_frame>
    <description>Percentage of acute kidney injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dose of vancomycin</measure>
    <time_frame>Through study completion, an average of 2 weeks</time_frame>
    <description>Average of the daily dose of vancomycin calculated in mg per kg of total body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operational Impact</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Evaluation of the impact on pharmacist's time required for monitoring vancomycin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Vancomycin</condition>
  <condition>Adult</condition>
  <condition>Area Under Curve</condition>
  <arm_group>
    <arm_group_label>Bayesian method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard method</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vancomycin dose adjustment using the Bayesian method</intervention_name>
    <description>This intervention is the experimental method. The AUC/MIC target is 400-600 mg*hour/L.</description>
    <arm_group_label>Bayesian method</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vancomycin dose adjustment using the trough level method</intervention_name>
    <description>This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.</description>
    <arm_group_label>Standard method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age;&#xD;
&#xD;
          -  Hospitalized patients&#xD;
&#xD;
          -  Suspected or confirmed infection;&#xD;
&#xD;
          -  Anticipated IV vancomycin treatment for 24 hours or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with renal replacement therapy (peritoneal dialysis, continuous renal&#xD;
             replacement therapy or hemodialysis);&#xD;
&#xD;
          -  Treatment of vancomycin in continuous infusion;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beno√Æt Crevier, PharmD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles-Le Moyne Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles-Le Moyne Hospital</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CR-CSSS Champlain-Charles-Le Moyne</investigator_affiliation>
    <investigator_full_name>Benoit Crevier</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bayesian approach</keyword>
  <keyword>Dose adjustments</keyword>
  <keyword>trough</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

